• Corpus ID: 46604972

THE ROLE OF CYP 3 A 4 / 5 IN ALPRAZOLAM METABOLISM

@inproceedings{Allqvist2010THERO,
  title={THE ROLE OF CYP 3 A 4 / 5 IN ALPRAZOLAM METABOLISM},
  author={Annika Allqvist},
  year={2010}
}
Cytochrome P450 3A (CYP3A) enzyme family is involved in the metabolism of about 50 % of all drugs in clinical use. Among CYP3A, CYP3A4 and CYP3A5 are the major enzymes in adults; CYP3A5 is polymorphic and primarily expressed in black populations. CYP3A5 may therefore contribute significantly to the metabolism of CYP3A substrates in African populations. The impact of CYP3A5 expression on drug metabolism by CYP3A is fairly unknown. Therefore, a tool for assessment of both CYP3A4 and CYP3A5 using… 

Figures and Tables from this paper

References

SHOWING 1-10 OF 87 REFERENCES

Significance of the Minor Cytochrome P450 3A Isoforms

  • A. Daly
  • Biology, Medicine
    Clinical pharmacokinetics
  • 2006
TLDR
Certain combined CYP3A4/CYP3A5 haplotypes show differential susceptibility to prostate cancer and there is a nonsignificant increase in the risk of small-cell lung cancer for a CYP 3A5* 1/*1 genotype.

Comparative analysis of CYP3A expression in human liver suggests only a minor role for CYP3A5 in drug metabolism.

TLDR
The data indicate that CYP3A4, CYp3A5, CYP 3A43, and PXR hepatic mRNA expression correlate, indicating common regulatory features, and that the contribution of CYP2A5 to hepatic drug metabolism in Caucasians is insignificant.

The Development of a Cocktail CYP2B6, CYP2C8, and CYP3A5 Inhibition Assay and a Preliminary Assessment of Utility in a Drug Discovery Setting

TLDR
In this study, a single cocktail inhibition assay for the three enzymes is developed and its utility in drug discovery is assessed and the potential impact of these findings on a cytochrome P450 inhibition strategy is discussed.

Inhibition of CYP3A4 and CYP3A5 catalyzed metabolism of alprazolam and quinine by ketoconazole as racemate and four different enantiomers

TLDR
KTZ racemate and enantiomers showed differential inhibitory effects of quinine and alprazolam metabolism, indicating that structural differences among the enantiomer would be related to their inhibitory potency on these two enzymes.

Pharmacokinetics of midazolam and 1'-hydroxymidazolam in Chinese with different CYP3A5 genotypes.

TLDR
The results indicated that the pharmacokinetics of midazolam and 1'-hydroxymidrazolam was independent of CYP3A5 expression, and the clinical consequence might be insignificant.

Simultaneous assessment of CYP3A4 and CYP1A2 activity in vivo with alprazolam and caffeine.

TLDR
It is concluded that ALP and CAF can be administered simultaneously for the assessment of CYP activity and plasma concentrations 6, 8, 10, and 24 h after drug ingestion reflect AUC of ALP andCAF and therefore in-vivo CYP3A4 and CYP1A2 activity, respectively.

Genetic variability in CYP3A5 and its possible consequences.

TLDR
This review collates currently available data on CYP3A5 polymorphisms, provides information on the population frequency of each genetic variant in major ethnic groups, and describes in vitro and in vivo studies that have attempted to identify genotype-phenotype associations.

Differential catalytic properties in metabolism of endogenous and exogenous substrates among CYP3A enzymes expressed in COS-7 cells.

Biotransformation of alprazolam by members of the human cytochrome P4503A subfamily.

TLDR
In adult human liver the CYP3A subfamily members are the principal enzymes involved in the 1'- and 4-hydroxylation of alprazolam, and clinically significant drug drug interactions between alpazolam and other CYP 3A substrates are to be expected.

In Vitro/in Vivo scaling of alprazolam metabolism by CYP3A4 and CYP3A5 in humans

TLDR
An in vitro/in vivo scaling of alprazolam metabolism using human liver microsomes and human CYP3A4 and CYP 3A5 recombinants is carried out and the values of CLint, in vivo predicted, were within 2.5 times of the observed value calculated from literature data.
...